1. Home
  2. BDTX vs JRVR Comparison

BDTX vs JRVR Comparison

Compare BDTX & JRVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BDTX
  • JRVR
  • Stock Information
  • Founded
  • BDTX 2014
  • JRVR 2002
  • Country
  • BDTX United States
  • JRVR Bermuda
  • Employees
  • BDTX N/A
  • JRVR N/A
  • Industry
  • BDTX Biotechnology: Biological Products (No Diagnostic Substances)
  • JRVR Property-Casualty Insurers
  • Sector
  • BDTX Health Care
  • JRVR Finance
  • Exchange
  • BDTX Nasdaq
  • JRVR Nasdaq
  • Market Cap
  • BDTX 323.2M
  • JRVR 241.0M
  • IPO Year
  • BDTX 2020
  • JRVR 2005
  • Fundamental
  • Price
  • BDTX $3.21
  • JRVR $6.94
  • Analyst Decision
  • BDTX Strong Buy
  • JRVR Buy
  • Analyst Count
  • BDTX 4
  • JRVR 6
  • Target Price
  • BDTX $15.50
  • JRVR $11.17
  • AVG Volume (30 Days)
  • BDTX 1.0M
  • JRVR 237.3K
  • Earning Date
  • BDTX 11-04-2024
  • JRVR 11-11-2024
  • Dividend Yield
  • BDTX N/A
  • JRVR 2.88%
  • EPS Growth
  • BDTX N/A
  • JRVR N/A
  • EPS
  • BDTX N/A
  • JRVR N/A
  • Revenue
  • BDTX N/A
  • JRVR $815,639,000.00
  • Revenue This Year
  • BDTX N/A
  • JRVR N/A
  • Revenue Next Year
  • BDTX N/A
  • JRVR $8.37
  • P/E Ratio
  • BDTX N/A
  • JRVR N/A
  • Revenue Growth
  • BDTX N/A
  • JRVR 23.89
  • 52 Week Low
  • BDTX $1.62
  • JRVR $6.12
  • 52 Week High
  • BDTX $7.66
  • JRVR $15.02
  • Technical
  • Relative Strength Index (RSI)
  • BDTX 29.72
  • JRVR 58.48
  • Support Level
  • BDTX $3.13
  • JRVR $6.14
  • Resistance Level
  • BDTX $3.42
  • JRVR $7.19
  • Average True Range (ATR)
  • BDTX 0.25
  • JRVR 0.21
  • MACD
  • BDTX 0.01
  • JRVR 0.12
  • Stochastic Oscillator
  • BDTX 7.95
  • JRVR 76.19

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

About JRVR James River Group Holdings Ltd.

James River Group Holdings Ltd owns and operates a group of specialty insurance and reinsurance companies. It reports business into three segments. The Excess and Surplus Lines segment, which is the key revenue driver, offers commercial excess and surplus lines liability and excess property insurance products; The Specialty Admitted Insurance segment focuses on niche classes within the standard insurance markets with a primary focus on fronting business, where it retains a minority share of the risk and seek to earn fee income by allowing other carriers and producers to use its licensure, ratings, expertise and infrastructure. and the Corporate and other segment consists of the management and treasury activities of holding companies, equity compensation for the group.

Share on Social Networks: